{
    "clinical_study": {
        "@rank": "70513", 
        "arm_group": {
            "arm_group_label": "MEK162 + panitumumab", 
            "arm_group_type": "Experimental", 
            "description": "Phase Ib: Dose escalation. Phase II: 4 different patient populations: 1) patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy. 2) patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy. 3) patients with WT RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pretreated with EGFR tyrosine kinase inhibitor therapy. 4) patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to\n      assess the anti-tumor activity of MEK162 in combination with panitumumab."
        }, 
        "brief_title": "Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  Metastatic colorectal cancer\n\n          -  Progression on or following standard therapy, or no standard therapy (phase Ib).\n             Progression on or following at least 2-prior fluoropyrimidine-containing chemotherapy\n             regimens (phase II)\n\n          -  Written documentation of mutant or wild-type RAS\n\n          -  Life expectancy \u2265 3 months\n\n          -  ECOG performance status \u2264 2\n\n        Exclusion Criteria:\n\n        Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other\n        EGFR inhibitors\n\n          -  Previous treatment with MEK-inhibitors\n\n          -  History of severe infusion reactions to monoclonal antibodies.\n\n          -  Symptomatic or untreated leptomeningeal disease\n\n          -  Symptomatic brain metastasis\n\n          -  Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as\n             assessed by ophthalmologic examination at baseline that would be considered a risk\n             factor for CSR/RVO and history of keratitis.\n\n          -  Acute or chronic pancreatitis\n\n          -  Clinically significant cardiac disease\n\n          -  Not adequate hematologic, renal and hepatic function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927341", 
            "org_study_id": "CMEK162X2116", 
            "secondary_id": "2013-001986-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "MEK162 + panitumumab", 
                "description": "MEK162 plus panitumumab combination", 
                "intervention_name": "MEK162", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEK162 + panitumumab", 
                "intervention_name": "Panitumumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "MEK162,", 
            "panitumumab,", 
            "mutant RAS,", 
            "wild-type RAS,", 
            "metastatic colorectal cancer,", 
            "adult mCRC patient"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "rbishop@mednet.ucla.edu", 
                    "last_name": "Rosa Bishop", 
                    "phone": "310-582-4069"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "University of California at Los Angeles Dept of Onc"
                }, 
                "investigator": {
                    "last_name": "Zev A. Wainberg", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oneillg@mskcc.org", 
                    "last_name": "Gerry O'Neill", 
                    "phone": "646-227-2129"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Oncology Dept"
                }, 
                "investigator": {
                    "last_name": "Rona B. Yeager", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 3", 
                        "country": "France", 
                        "zip": "31052"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif Cedex", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f6ln", 
                        "country": "Germany", 
                        "zip": "50924"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20162"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066 CX"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "state": "Catalunya", 
                        "zip": "08035"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Canada: Health Canada", 
                "France: Comit\u00e9 consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: National Institute of Health", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ]
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Estimation of maximum tolerated dose (MTD)", 
                "measure": "Incidence of Dose limiting toxicities in cycle 1 (Phase Ib)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Assess clinical efficacy as per RECIST 1.1", 
                "measure": "Overall Response rate (Phase II)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927341"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequency and severity of AEs, SAEs, changes in laboratory values, vital signs, and electrocardiograms", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "one year"
            }, 
            {
                "description": "Assess preliminary anti-tumor activity as per RECIST 1.", 
                "measure": "Overall response rate (Phase lb)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "assess anti-tumor activity as per RECIST 1.1", 
                "measure": "Progression free- survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "Overall survival (Phase II)", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }, 
            {
                "description": "assess anti-tumor activity as per RECIST 1.1", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "assess anti-tumor activity as per RECIST 1.1", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}